Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ImmuPharma PLC (IMM.L)
London, GB
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.33% | -7.42% | -6.00% | -46.39% | -36.69% | -30.56% | +57.12% | +38.65% | -51.85% | -84.89% | -86.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+38.3% ★ Q4'25: +100.0% (vs Q3'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'25: +471.4% (vs Q3'24)
-
Share dilution Biotechnology: -3.4%+17.8% Q4'25: -100.0% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
164.8K
est: 100.0K (+64.8%)
|
150.5K
est: 100.0K (+50.5%)
|
81.3K
est: 100.0K (-18.7%)
|
77.9K
est: 100.0K (-22.1%)
|
126.7K
est: 100.0K (+26.7%)
|
118.4K
est: 100.0K (+18.4%)
|
—
est: 100.0K (-100.0%)
|
—
est: 100.0K (-100.0%)
|
100.0K
100.0K – 100.0K
+0.0% YoY
|
100.0K
100.0K – 100.0K
+0.0% YoY
|
100.0K
100.0K – 100.0K
+0.0% YoY
|
100.0K
100.0K – 100.0K
+0.0% YoY
|
100.0K
100.0K – 100.0K
+0.0% YoY
|
| EBITDA |
-6.19M
est: 20.0K (-31,056.5%)
|
-6.86M
est: 20.0K (-34,376.7%)
|
-7.82M
est: 20.0K (-39,187.0%)
|
-6.65M
est: 20.0K (-33,361.7%)
|
-6.84M
est: 20.0K (-34,321.7%)
|
-8.70M
est: 20.0K (-43,617.2%)
|
-2.61M
est: 20.0K (-13,155.7%)
|
-2.51M
est: 20.0K (-12,637.7%)
|
20.0K
20.0K – 20.0K
+0.0% YoY
|
20.0K
20.0K – 20.0K
+0.0% YoY
|
20.0K
20.0K – 20.0K
+0.0% YoY
|
20.0K
20.0K – 20.0K
+0.0% YoY
|
20.0K
20.0K – 20.0K
+0.0% YoY
|
| EBIT |
-6.31M
est: 20.0K (-31,666.6%)
|
-6.99M
est: 20.0K (-35,071.7%)
|
-7.95M
est: 20.0K (-39,852.0%)
|
-6.74M
est: 20.0K (-33,801.7%)
|
-7.02M
est: 20.0K (-35,176.8%)
|
-8.82M
est: 20.0K (-44,187.2%)
|
-2.68M
est: 20.0K (-13,475.7%)
|
-2.54M
est: 20.0K (-12,814.2%)
|
20.0K
20.0K – 20.0K
+0.0% YoY
|
20.0K
20.0K – 20.0K
+0.0% YoY
|
20.0K
20.0K – 20.0K
+0.0% YoY
|
20.0K
20.0K – 20.0K
+0.0% YoY
|
20.0K
20.0K – 20.0K
+0.0% YoY
|
| Net Income |
-5.32M
est: -17.70M (+69.9%)
|
-6.22M
est: -13.16M (+52.7%)
|
-7.21M
est: -17.74M (+59.4%)
|
-6.12M
est: -12.08M (+49.3%)
|
-6.86M
est: -11.66M (+41.2%)
|
-8.17M
est: -12.08M (+32.3%)
|
-2.48M
est: -17.70M (+86.0%)
|
-1.81M
est: -13.16M (+86.3%)
|
-17.74M
-17.74M – -17.74M
-34.8% YoY
|
-12.08M
-12.08M – -12.08M
+31.9% YoY
|
-11.66M
-11.66M – -11.66M
+3.4% YoY
|
-12.08M
-12.08M – -12.08M
-3.6% YoY
|
-12.08M
-12.08M – -12.08M
+0.0% YoY
|
| SGA |
1.40M
est: 613.8K (+127.8%)
|
1.52M
est: 613.8K (+147.7%)
|
1.66M
est: 613.8K (+170.5%)
|
1.83M
est: 613.8K (+198.3%)
|
1.77M
est: 613.8K (+187.6%)
|
1.63M
est: 613.8K (+165.2%)
|
1.12M
est: 613.8K (+82.3%)
|
1.16M
est: 613.8K (+89.2%)
|
613.8K
613.8K – 613.8K
+0.0% YoY
|
613.8K
613.8K – 613.8K
+0.0% YoY
|
613.8K
613.8K – 613.8K
+0.0% YoY
|
613.8K
613.8K – 613.8K
+0.0% YoY
|
613.8K
613.8K – 613.8K
+0.0% YoY
|
| EPS |
-0.05
est: -0.04 (-6.8%)
|
-0.05
est: -0.03 (-50.3%)
|
-0.05
est: -0.04 (-21.8%)
|
-0.04
est: -0.03 (-37.6%)
|
-0.03
est: -0.03 (-22.5%)
|
-0.03
est: -0.03 (-12.1%)
|
-0.01
est: -0.04 (+85.9%)
|
0.00
est: -0.03 (+88.3%)
|
-0.04
-0.04 – -0.04
-34.8% YoY
|
-0.03
-0.03 – -0.03
+31.9% YoY
|
-0.03
-0.03 – -0.03
+3.4% YoY
|
-0.03
-0.03 – -0.03
-3.6% YoY
|
-0.03
-0.03 – -0.03
+0.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Timothy Paul McCarthy FCCA | Chairman & Chief Executive Officer | 294.0K | male |
| Timothy Gary Franklin | Chief Operating Officer & Director | 252.0K | — |
| Lisa Baderoon | Head of Investor Relations & Non Executive Director | 132.0K | female |
| Sébastien R. Goudreau | Chief Scientific Officer & Director | 3.0K | — |
| Laura Mauran-Ambrosino | Head of Research & Development | — | — |
| Ashley Louise Clarke | Chief Financial Officer, Company Secretary & Director | — | female |
| Lara E. Sucheston-Campbell | Head of Clinical & Medical Affairs | — | female |
| Jean-Marie Geiger | Head of Clinical Development | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMM.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
